AngioDynamics price target lowered to $16 from $18 at Canaccord

Canaccord lowered the firm’s price target on AngioDynamics (ANGO) to $16 from $18 and keeps a Buy rating on the shares. The firm said they delivered a good FQ3 with a revenue beat and increased guidance. However, they think the initial negative stock reaction may have come from optics of the company’s adj. EBITDA guidance, which was set at $10M-$12M for FY26. They noted AngioDynamics raised its revenue, adjusted EBITDA, and adjusted EPS guidance ranges, while maintaining its gross margin guidance